Shanghai Pharmaceuticals: Notification of Approval for Clinical Trial of New Indication B019

Shanghai Pharmaceuticals announced on the evening of July 29th that its subsidiary Shangyu Biomedical Therapy's independently developed "B019" has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, allowing it to conduct clinical trials for refractory systemic lupus erythematosus.